Orphazyme shares spike 95% in afternoon trading on eve of FDA PDUFA decision

CalypsoArt/iStock via Getty Images

• Shares of Orphazyme (NASDAQ:ORPH) have suddenly shot up 95% in afternoon trading on the eve of an expected FDA decision on its application for Arimoclomol for the treatment of Niemann-Pick Disease Type C ("NPC").
• Trading in the stock was already briefly halted three times this morning for 5-10 minutes each instance.
• Orphazyme is also partnered with CytRx (OTCQB:CYTR), which is up 9.5%.